STRYKER RECALLED — OCTOBER 2024
5-Star Google Reviews
★★★★★
The Cartiva Synthetic Cartilage Implant was recalled by Stryker in October 2024 after thousands of patients suffered painful failures requiring revision surgery. If you had a Cartiva implant and experienced complications, you may qualify for the federal MDL now consolidated in Arkansas.
Documented failure rates of up to 79% within two years. No fees unless we recover.
FAILURE RATE
In the news: Baker Legal Team has launched a national Cartiva implant litigation practice. Read the press release →
You may qualify
The Cartiva Synthetic Cartilage Implant — a polyvinyl alcohol device placed in the big-toe (MTP) joint — was implanted in tens of thousands of patients between July 2016 and the October 2024 recall.
Persistent pain, swelling, stiffness, difficulty walking, implant loosening or migration, bone reabsorption, or another failure following your procedure.
Revision surgery, removal, fusion, or another corrective procedure to address the failed implant. Not sure of the dates? A case manager will help you confirm.
Independent peer-reviewed analysis documented Cartiva implant failure rates as high as 79% within two years — nearly six times what Stryker disclosed to the FDA.
Source: Peer-reviewed clinical analysis
What Stryker reported to the FDA when the Cartiva implant was approved in 2016.
Independent post-market studies have documented Cartiva failure rates as high as 64%.
Stryker recalled all four Cartiva implant sizes (6mm, 8mm, 10mm, 12mm) in October 2024.
Federal Cartiva lawsuits consolidated in the U.S. District Court for the Eastern District of Arkansas. First bellwether trials scheduled for 2026.
FAQ
Free consultations. No fees unless we recover. Cases handled with nationwide coverage — documents signed electronically.
The Cartiva Synthetic Cartilage Implant is a small polyvinyl alcohol device implanted in the big-toe joint to treat arthritis. It was marketed as an alternative to fusion surgery.
Symptoms include persistent pain, swelling, stiffness, difficulty walking, implant displacement, or having undergone revision or fusion surgery.
Nothing upfront. We work on a contingency fee — you only pay if we recover compensation for you.
No. We handle Cartiva cases with nationwide coverage. Documents are signed electronically.
Mass tort cases typically take 1 to 3 years. The MDL consolidation may accelerate timelines.
We help you obtain medical records as part of the free review.
You may still want to monitor it. We can advise you based on current symptoms.
Most mass tort cases resolve through global settlements. Few claimants ever appear in court.
See if you qualify
The Cartiva MDL is moving fast — bellwether trials are scheduled for 2026, and defendants are under increasing pressure to negotiate a global settlement. Filing today preserves your seat at the table.
Takes about 60 seconds. No obligation.
Failed Cartiva toe implant — or diagnosed with T-cell lymphoma after taking Dupixent? You may be entitled to compensation. No fees unless we win.
